Podcasts about hydroxyurea

Meet Leia and Krison Burroughs, who are still in the midst of their family building journey. On today's show, Leia and Kriston tell Ali about how Kriston was diagnosed with sickle cell anemia when he was just a year old, and how they had no idea that the sickle cell drug, Hydroxyurea, would have a direct effect on his fertility. They also talk about microTESE surgery, the five hysteroscopies Leia had, and how the whole infertility journey has been hard on their marriage. They explain why they fired their OB, why they pivoted to embryo adoption, why they preferred doing that over donor sperm, and where they are now in the journey. Says Leia: "Did you know that 24% of men with Sickle Cell Anemia experience infertility due to the effects of the disease? Did you know that Sickle Cell Anemia affects about 100,000 people or that it occurs 1 in every 365 Black births in the U.S.?" Says Kriston, "Black folks need to start talking about our fertility treatments."  For more, follow IG: @ladibuddafly08 and @owtspokeneducator and @iamkristonb TOPICS COVERED IN THIS EPISODE: Infertility; Sickle cell anemia; Hydroxyurea; fibroids; embryo adoption; donor sperm; therapy; marriage issues; health insurance; black maternal healthcare; fertility grants EPISODE SPONSORS: WORK OF ART Children's Book about IVF https://www.infertileafgroup.com/books Do not miss Ali's children's book about IVF! It's been getting rave reviews. “Work of ART” is the story of an IVF kiddo the day he learns he is a “work of ART” (born via IVF and Assisted Reproductive Technology). For young readers 4-8. Hardcover. Written by Ali Prato; Illustrated by Federico Bonifacini. Personalized and non-personalized versions are available. Order yours now at https://www.infertileafgroup.com/books For bulk orders of 10 or more books, go to https://www.infertileafgroup.com/bulk-order-request FERTILITY RALLY @fertilityrally www.fertilityrally.com No one should go through infertility alone. Join the Worst Club with the Best Members at fertilityrally.com. We offer 5 to 6 support groups per week, three private Facebook groups, tons of curated IRL and virtual events, and an entire community of more than 500 women available to support you, no matter where you are in your journey. Join today at link in bio on IG @fertilityrally or at www.fertilityrally.com/membership SAVE $40 on an annual membership with code RALLY2024 NATALIST www.natalist.com Natalist is on a mission to improve your fertility journey with evidence-backed essentials to support your needs, from vegan prenatal packets to easy-to-use, plastic-neutral ovulation tests and fertility-friendly lube. Natalist is offering my community 25% off your first order at Natalist.com with promo code INFERTILEAF. RECEPTIVA DX https://receptivadx.com/ ReceptivaDx is the singular test capable of identifying endometriosis,progesterone resistance, and endometritis in one comprehensive analysis. These conditions are often the hidden culprits behind unexplained infertility, directly impacting the success rates of IVF treatments. Ask for the Receptvia DX test today, and use code INFERTILEAF24 for $75 off. Learn more about your ad choices. Visit podcastchoices.com/adchoices Learn more about your ad choices. Visit podcastchoices.com/adchoices

In this week's episode we'll discuss molecular mimicry in aplastic anemia, novel experiments show that antigens associated with viral infections can mimic epitopes presented on hematopoietic progenitor cells. Then, we'll learn about prophylaxis with subcutaneous emicizumab in infants with hemophilia. Finally we'll see how hydroxyurea is associated with a significant reduction in infections among children with sickle cell anemia in Uganda.Articles featured this week:Virus-reactive T cells expanded in aplastic anemia eliminate hematopoietic progenitor cells by molecularmimicryEmicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-labeltrialHydroxyurea reduces infections in children with sickle cell anemia in Uganda

Sickle cell disease (SCD) patients are at risk of developing multiple complications from transfusions, including alloimmunization to red blood cell antigens, delayed hemolytic transfusion reactions and hyperhemolysis syndrome (HHS). While HHS is a rare complication of repeat blood transfusions in patients with SCD, clinicians and the laboratory have important roles in its detection and management. In this podcast, Wally R. Smith, MD, the inaugural Florence Neal Cooper Smith Professor of Sickle Cell Disease at Virginia Commonwealth University shares insights to screening for and managing HHS.   About Our Speaker:  Wally R. Smith, MD, is an experienced implementation scientist and expert in clinical and health services research in sickle cell disease (SCD). He serves as Vice Chair for Research of the Division of General Internal Medicine at Virginia Commonwealth University (VCU) and was Scientific Director of the Center on Health Disparities at VCU. Dr. Smith has authored over 100 publications and served as an investigator on over 50 grants and contracts. He has been principal investigator on 26 federal or foundation-funded grants and contracts including: Pain in Sickle Cell Epidemiology Study (PiSCES), the largest and most detailed adult cohort that changed our understanding of SCD pain in adults and, since 2012, Start Healing in Patients with Hydroxyurea, the first-ever randomized controlled trial of implementation science in SCD.

This week, Jonathan is joined by Sophie Lanzkron, Professor of Medicine in the Division of Hematology at the Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. The pair explores sickle cell disease and advancements in its treatment, including hydroxyurea and blood transfusions, as well as advancements in haplotype transplant and gene therapy. They further discuss challenges in diagnosis and treatment, and how the condition affects quality of life. Use the following timestamps to navigate the content in this episode: (00:00)-Introduction (02:33)-Inspiration to work in haematology and sickle cell disease (05:00)-Sickle cell disease: what is it and how does it affect quality of life (08:30)-Efficiency and use of hydroxyurea (13:00)-Infusion clinic outcomes versus emergency department outcomes (16:08)-Treating patients with sickle cell disease by blood transfusions (17:40)-Global prevalence and burden of sickle cell disease (20:20)-Challenges faced by patients during diagnosis and treatment (23:53)-Novel sickle cell disease healthcare delivery model (26:27)-Perfecting treatment for sickle cell disease (29:15)-Research focus in the future (31:22)-Lanzkron's three wishes for the future

In this week's episode we will review a study in sub-Saharan Africa where treatment of sickle cell anemia with hydroxyurea is associated with a lower incidence of malaria. New research suggests mild myelosuppression associated with hydroxyurea treatment may actually have a salutary effect. Next, a potential new treatment approach in lower GI acute GVHD. Adding an interleukin-22 therapy to corticosteroid treatment was well tolerated with a high rate of response in this very challenging patient population. Finally, common AML driver mutations such as FLT3ITD (or internal tandem duplications) orchestrate distinct transcriptional and epigenetic programs based on different genetic contexts. In the context of a common pediatric AML mutation, FLT3ITD selectively activated type I interferon signaling, suggesting a distinct therapeutic vulnerability.

Dr Emmanuela E Ambrose tells us about the SPHERE trial on hydroxyurea dose escalation for primary stroke prevention in children with sickle cell disease in TanzaniaRead the full article:Hydroxyurea with dose escalation for primary stroke risk reduction in children with sickle cell anaemia in Tanzania (SPHERE)Continue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

In this week's episode we will first review a new clinical trial evidence that for patients with sickle cell anemia in resource limited settings, both low and moderate dose hydroxyurea are effective for secondary stroke prevention. Next, a research article showing how secreted mutant calreticulin functions as a “rogue cytokine” in myeloproliferative neoplasms, acting in a paracrine manner to promote growth of nearby tumor cells. Finally, we'll review new research on the pathobiology of adult and pediatric Burkitt lymphoma. With the help of whole-genome sequencing, investigators unraveled distinct subgroups, which may provide a new framework for epidemiology, diagnosis, and treatment of these lymphomas.

In this podcast episode, Prithviraj Bose, MD, and Andrew Kuykendall, MD, discuss their contemporary approaches to the treatment of patients with essential thrombocythemia. The topics covered include:When to use cytoreduction therapies and which therapies to use in low-risk patientsType 1 and type 2 CALR mutations and addressing patient concerns with data from sequencing reportsExperts' thoughts on therapy options in higher-risk patientsPresenters:Prithviraj Bose, MDAssociate ProfessorDivision of Cancer MedicineDepartment of LeukemiaThe University of TexasMD Anderson Cancer CenterHouston, TexasAndrew Kuykendall, MDAssistant Professor Department of Oncologic SciencesUniversity of South FloridaAssistant MemberMalignant HematologyH. Lee Moffitt Cancer CenterTampa, Florida Content for this program was supported by educational grants from GSK, Incyte Corporation, and PharmaEssentia Corp.Link to the full program, including downloadable slides and an on-demand webcast from the live event:bit.ly/3XF3cSF

In this podcast episode, Raajit Rampal, MD, PhD, and Brady L. Stein, MD, MHS, discuss their contemporary approaches to the treatment of patients with polycythemia vera. The topics covered include:Patient presentation and goals of frontline therapyConsiderations for second-line therapy in the setting of treatment intoleranceExperts' thoughts on the potential of early intervention to alter disease progressionPresenters:Raajit Rampal, MD, PhDAssociate MemberAssociate Attending PhysicianLeukemia ServiceDepartment of MedicineMemorial Sloan Kettering Cancer CenterNew York, New YorkBrady L. Stein, MD, MHSProfessor of MedicineDepartment of Hematology/OncologyNorthwestern University Feinberg School of MedicineChicago, IllinoisContent for this program was supported by educational grants from GSK, Incyte Corporation, and PharmaEssentia Corp.Link to the full program, including downloadable slides and an on-demand webcast from the live event:https://bit.ly/3X3x6jX

Several Cochrane Reviews evaluate treatments for sickle cell disease, which can cause a huge burden for patients and their families. The review on the effects of hydroxyurea was updated in September 2022 by Angela Rankine-Mullings from the Sickle Cell Unit, Caribbean Institute for Health Research at The University of the West Indies in Jamaica and Sarah Nevitt, from the Department of Health Data Science, University of Liverpool in UK. We asked Angela to outline the need for the review and its latest findings in this podcast.

Several Cochrane Reviews evaluate treatments for sickle cell disease, which can cause a huge burden for patients and their families. The review on the effects of hydroxyurea was updated in September 2022 by Angela Rankine-Mullings from the Sickle Cell Unit, Caribbean Institute for Health Research at The University of the West Indies in Jamaica and Sarah Nevitt, from the Department of Health Data Science, University of Liverpool in UK. We asked Angela to outline the need for the review and its latest findings in this podcast.

In this week's episode we'll discuss an undescribed role for NOX2 in maintaining lung homeostasis through suppression of alveolar macrophage activation. We'll also cover results of a phase 3 randomized trial that compares the safety and efficacy of hydroxyurea and peginterferon alfa-2a in patients with high-risk polycythemia vera and essential thrombocythemia (or PV and ET, respectively). Finally, we'll go more in depth on the emerging treatment landscape for PV, and the limits of current clinical trial endpoints.

In this second of 2 podcasts episodes on the management of painful vaso-occlusive crises in patients with sickle cell disease, listen to Alison Towerman, RN, MSN, CPNP, and Michael R. DeBaun, MD, MPH, discuss  available treatment options for the prevention of painful vaso-occlusive events, and provide emergency department and outpatient setting recommendations on the proper use and indications for hydroxyurea, L-glutamine, and P-selecting blocking antibody crizanlizumab. This activity is available for 0.25 ANCC and 0.25 AAPA credits, with 0.25 credits applicable for pharmacology credit for NPs. To receive credit for this program, go to pce.is/sickle.Contributors:Michael R. DeBaun, MD, MPHDirectorVanderbilt-Meharry Center for Excellence in Sickle Cell DiseaseProfessorPediatrics and MedicineVice Chair for Clinical and Translational ResearchDepartment of PediatricsJ.C. Peterson Chair in PediatricsNashville, TennesseeMichael R. DeBaun, MD, MPH: consulting, speaker, and advisory board fees: Forma, GBT, Novartis, and Vertix.Alison Towerman, RN, MSN, CPNPPediatric Nurse PractitionerDepartment of Pediatrics, Division of Hematology/OncologyWashington University School of Medicine in St. LouisSt. Louis, Missouri Ms. Towerman has no relevant financial relationships to disclose.

#worldsicklecellday Health4Naija podcast by Dr. Ngozi Onuoha with mention of the newer therapies for sickle cell and disease modifying approach: Hydroxyurea, L-glutamine (Endari), Voxelotor (Oxbryta), Crizanlizumab-tmca (Adakveo), transfusion, exchange blood transfusion, bone marrow transplantation. Disclaimer: This is for education only. The data on medications may change at anytime. Please consult with your medical provider for any health related concerns. --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app Support this podcast: https://anchor.fm/health4naija/support

This episode covers hydroxyurea!

Avsnitt 54 handlar om blodsjukdomar, årets Nobelpris i medicin och lite om forskningsfinansieringens dunkla värld. Hör av er på @medforfattarna med tankar, tips och feedback!

On Episode 15, Dr. Z and Dr. C welcome Dr. Patrick McGann, an Associate Professor of Pediatrics at Cincinnati Children's Hospital (one of the best sickle cell centers in the country, maybe even the world!) Dr. McGann always knew he wanted to be a pediatrician when he was growing up in Boston, but little did he know where that childhood dream would take him. He talks about how his path led him toward his love for sickle cell and speaks on the work he has done in Angola, noting how differently the disease affects communities outside of the United States. Dr. C, Dr. Z and Dr. McGann also discuss the positive effects of Hydroxyurea in the sickle cell community, the small portion of patients who have experienced negative side effects from this therapy, and how this medication is used in patients with sickle cell. Dr. Ahmar Zaidi on Twitter Dr. Michael Callaghan on Twitter BloodStream Media For all inquiries: mailbag@bloodstreammedia.com (subject: Cheat Codes) Subscribe to and rate Cheat Codes Subscribe to and rate The BloodStream Podcast Subscribe to and rate The Ask The Expert Podcast Subscribe to and rate BloodStream Journeys Connect with BloodStream Media: Find all of our bleeding disorders podcasts on BloodStreamMedia.com BloodStream on Facebook BloodStream on Twitter

Hyperleukocytosis & Leukostasis + MCQ from chapter titled Emergencies in Hematology and Oncology in Baliga's Textbook of Internal Medicine available at MasterMedFacts.com authored by Thorvardur Halfdanarson,MD Professor of Oncology Mayo Clinic, Rochester, MN & Eric Engelman, MD Clinical Hematologist/Oncologist Dubuque, Iowa Not Medical Advice or Opinion  

CME credits: 0.50 Valid until: 17-12-2020 Claim your CME credit at https://reachmd.com/programs/cme/novel-interventions-for-preventing-reducing-pain-crisis-in-sickle-cell-disease/10863/ Sickle cell disease (SCD) affects approximately 100,000 individuals in the United States. Vaso-occlusive crisis (VOC), characterized by the sudden onset of severe pain, is the most common reason for hospital visits in patients with SCD. However, despite the availability of guidelines on the recommended treatment, acute pain in SCD is often undertreated. Although opioids are recommended for severe acute pain episodes, the concern about addiction often results in clinicians failing to provide adequate pain control. Hydroxyurea is the only treatment that modifies the disease process in SCD; however, many providers are uncomfortable prescribing it, and many eligible patients with SCD remain inadequately treated. Now, new therapies are becoming available, and clinicians have a greater need for education about the efficacy and safety data of established and novel treatments for the management and prevention of VOCs. This activity will review the most recent clinical data and evidence-based updates and provide expert insights on preventing and reducing VOCs in sickle cell disease.

CME credits: 0.50 Valid until: 17-12-2020 Claim your CME credit at https://reachmd.com/programs/cme/novel-interventions-for-preventing-reducing-pain-crisis-in-sickle-cell-disease/10863/ Sickle cell disease (SCD) affects approximately 100,000 individuals in the United States. Vaso-occlusive crisis (VOC), characterized by the sudden onset of severe pain, is the most common reason for hospital visits in patients with SCD. However, despite the availability of guidelines on the recommended treatment, acute pain in SCD is often undertreated. Although opioids are recommended for severe acute pain episodes, the concern about addiction often results in clinicians failing to provide adequate pain control. Hydroxyurea is the only treatment that modifies the disease process in SCD; however, many providers are uncomfortable prescribing it, and many eligible patients with SCD remain inadequately treated. Now, new therapies are becoming available, and clinicians have a greater need for education about the efficacy and safety data of established and novel treatments for the management and prevention of VOCs. This activity will review the most recent clinical data and evidence-based updates and provide expert insights on preventing and reducing VOCs in sickle cell disease.

In Episode 2 of Cheat Codes, Dr. Z makes the case for hydroxyurea during the What's Happenin' Now segment, Dr. Mike provides clarity on what "hemoglobin" actually is during our Warrior Word Of The Day segment, the guys interview Dr. Baba Inusa during ASCAT 2019 in London England, and Dr. Mike opens the research book once again in the Red Blood Cell Research Review.  Enjoy this episode of Cheat Codes, produced by BloodStream Media. Be sure to spread the word and to subscribe to Cheat Codes wherever you listen to podcasts!   Dr. Ahmar Zaidi (@ahmaruroojzaidi) on Twitter Dr. Mike Callaghan (@michaelucallag1) on Twitter BloodStream Media (@bloodstreaminfo) on Twitter Subscribe to Cheat Codes   ASCAT 2019 Stroke Prevention Trial in Sickle Cell Anemia (STOP)

  Episode 8: John J. Strouse, MD, PhD, and Julie Kanter, MD, join guest host Ify Osunkwo, MD, of Levine Cancer Institute/Atrium Health in Charlotte, N.C., to discuss current therapies for sickle cell disease, as well as new treatments and cures under development. Clinical Correlations:Ilana Yurkiewicz, MD, tackles informed consent and the capacity to choose in cancer care with a focus on the research setting. Dr. Yurkiewicz is a fellow in hematology and oncology at Stanford University and is a columnist for Hematology News. More from Dr. Yurkiewicz here.     SHOW NOTESBY EMILY BRYER, DO Resident in the department of internal medicine, University of Pennsylvania Health System. Sickle cell disease is a multi-organ system vascular disease that affects both children and adults. Pathophysiology in sickle cell disease includes increased expression of adhesion molecules resulting in vessel obstruction, activation of coagulation cascade and inflammatory cytokines, and a relative deficiency of nitric oxide that limits blood vessel dilatation. Universal newborn screening has translated into earlier diagnoses of sickle cell disease with improved outcomes. Therapeutics for sickle cell disease are limited, with only two FDA approved medications: Hydroxyurea (increases fetal hemoglobin) Decreases leukocyte counts, increases available nitric oxide. Endari (L-glutamine) Helps to decrease inflammation in the blood cell and improve nitric oxide availability. Blood transfusions are used conservatively. Comprehensive Center (multidisciplinary team) remains the gold standard for sickle cell disease treatment, however many patients are limited by geographic location and/or by medical insurance.   EMBRACE (Education and Mentoring to Bring Access to CarE) Network: Collaboration of eight states in the southeastern United States to improve medical care of patients with sickle cell disease. Primary goals include increasing the use of hydroxyurea and improving outreach to providers using telemedicine. New and emerging therapies for sickle cell disease: Selective inhibitors target the interaction between erythrocytes, leukocytes, and the endothelium inside of the blood vessel. Anticoagulants. Gene transplants and stem cell therapies to cure sickle cell disease and include both matched sibling donor transplant and half-matched donor transplant. Resources: 1. Phase 3 study of L-glutamine (NCT01179217) 2. Sickle cell disease, a review (N Engl J Med 2017; 376:1561-73) 3. Gene therapy approaches to sickle cell disease (Blood 2016 127:839-48) Contact us: podcasts@mdedge.com Twitter: @MDedgeHemOnc

Stuck on sickle cell disease? We hammer out the basics of diagnosis, common sickle cell variants and their manifestations, preventive medicine, acute and chronic pain management, opioid use, and how to recognize and treat common complications like anemia, fever and acute chest syndrome. Sickle cell expert, Sophie Lanzkron MD, Associate Professor of Medicine and Oncology and Director of the Sickle Cell Center for Adults at Johns Hopkins joins! Full show notes available at http://thecurbsiders.com/podcast. Join our mailing list and receive a PDF copy of our show notes every Monday. Rate us on iTunes, recommend a guest or topic and give feedback at thecurbsiders@gmail.com. Sponsor ACP's Internal Medicine Meeting 2019 April 11-13th in Philadelphia, PA. We'll see you there! Credits Written (including CME questions) and produced by: Justin Berk MD, Martha Brucato MD PhD, Beth Garbitelli MS1 Hosts: Paul Williams MD, Justin Berk MD, Matthew Watto MD Edited by: Matthew Watto MD Guest: Sophie Lanzkron MD MHS Time Stamps 00:00 Announcements, intro 02:30 A quick refresher on hemoglobinopathy 03:45 Guest bio 05:03 Guest one-liner, movie recommendation, career advice, picks of the week 10:53 ACP Internal Medicine Meeting 2019 (ad read) 12:33 Clinical case; defining sickle cell; pathophysiology 16:23 Different types of hemoglobinopathy genotypes and phenotypes 20:20 Preventive care for sickle cell disease 22:56 Taking a history at the initial visit in patient with sickle disease 26:40 Life expectancy in SCD 28:30 Hydroxyurea 30:40 Chronic red blood cell transfusion therapy; complications; monitoring 37:07 Silent cerebral infarcts and mild cognitive impairment in SCD  40:10 Chronic pain management; opioid use disorder in sickle cell disease 46:00 Acute pain crisis management; PCAs vs bolus therapy 54:08 Reticulocyte count in sickle cell disease 55:40 Itching, opioids and naloxone? 58:10 Red blood cell transfusion threshold in sickle cell disease (anemia) 60:03 Acute fever in SCD 61:48 Acute chest syndrome 66:45 Transition from pediatrics to adult medicine in sickle cell 68:00 Incentive spirometry to prevent acute chest syndrome 68:45 Take home points 70:00 Outro

Audio Journal of Global Health Issues, December 8th, 2007 Reporting from: American Society of Hematology Annual Meeting, December 8-11 2007, Atlanta No Use Of Hydroxyurea In Country With Most Sickle Cell Anemia ZAKARI ALIYU, Howard University, Washington DC REFERENCE: Late Breaking Special Session, AHA 2007 Nigeria has the highest incidence of sickle cell anemia in the world, with over 150,000 children being born each year with the disease. But a new study has shown that no one is using the standard therapy hydroxyurea to treat it. Derek Thorne got more from Zakari Aliyu of Howard University in Washington DC.